Active, not recruitingPhase 2NCT03619551
Conditioning SCID Infants Diagnosed Early
Studying T-B+ severe combined immunodeficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Center for International Blood and Marrow Transplant Research
- Principal Investigator
- Sung-Yun Pai, MD, MDNational Institutes of Health (NIH)
- Intervention
- Busulfan(drug)
- Enrollment
- 56 enrolled
- Eligibility
- 0-2 years · All sexes
- Timeline
- 2018 – 2028
Study locations (30)
- Univeristy of Alabama at Birmingham, Birmingham, Alabama, United States
- Mayo Clinic Arizona and Phoenix Children's Hospital, Phoenix, Arizona, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- UCLA Center for Health Sciences, Los Angeles, California, United States
- Rady Children's Hospital, San Diego, San Diego, California, United States
- University of California San Francisco Medical Center - Peds, San Francisco, California, United States
- University of Colorado - Children's Hospital, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Shands HealthCare & University of Florida, Gainesville, Florida, United States
- University of Miami/Jackson Memorial Hospital, Miami, Florida, United States
- All Children's Hospital, St. Petersburg, Florida, United States
- Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States
- Comer Children's Hospital/University of Chicago Medicine, Chicago, Illinois, United States
- Indiana University Hospital/Riley Hospital for Children, Indianapolis, Indiana, United States
- University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03619551 on ClinicalTrials.govOther trials for T-B+ severe combined immunodeficiency
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06851767Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene TherapyNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE1, PHASE2NCT01306019Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)National Institute of Allergy and Infectious Diseases (NIAID)